Taraxasterol inhibits IL-1β-induced inflammatory response in human osteoarthritic chondrocytes

Osteoarthritis (OA), a chronic degenerative joint disease, is a leading cause of disability among elderly patients. Taraxasterol, a pentacyclic-triterpene isolated from Taraxacum officinale, has been shown to have anti-inflammatory effects. However, the protective effect of taraxasterol on OA remain...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:European journal of pharmacology 2015-06, Vol.756, p.38-42
Hauptverfasser: Piao, Taikui, Ma, Zhiqiang, Li, Xin, Liu, Jianyu
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Osteoarthritis (OA), a chronic degenerative joint disease, is a leading cause of disability among elderly patients. Taraxasterol, a pentacyclic-triterpene isolated from Taraxacum officinale, has been shown to have anti-inflammatory effects. However, the protective effect of taraxasterol on OA remains unclear. In order to provide a scientific basis for the applicability of taraxasterol in OA, the anti-inflammatory effects of taraxasterol on IL-1β-stimulated osteoarthritic chondrocytes were investigated. Chondrocytes were pretreated with taraxasterol 1h before IL-1β treatment. The productions of MMP-1, MMP3, MMP13, PGE2 and NO were measured by ELISA and Griess reaction. The expression of COX-2, iNOS, and NF-κB was detected by western blot analysis. Our results demonstrated that taraxasterol dose-dependently suppressed MMP-1, MMP3, MMP13, PGE2 and NO production induced by IL-1β. The expression of COX-2 and iNOS was also inhibited by taraxasterol. Western blot analysis showed that taraxasterol suppressed IL-1β-induced NF-κB activation in a dose-dependent manner. Taken together, we found that taraxasterol protected human chondrocytes by inhibiting MMPs, NO and PGE2 production. Taraxasterol may be a useful agent for prevention and treatment of OA.
ISSN:0014-2999
1879-0712
DOI:10.1016/j.ejphar.2015.03.012